Tag: Tiara

TMVI with Tiara valve may be safe and feasible for patients...

A new study indicates that transcatheter mitral valve implantation (TMVI) with the Tiara valve (Neovasc) can be safely and successfully implanted in patients with...

TVT 2018: Tiara TMVI device featured in live case

Neovasc announced that its Tiara transcatheter mitral valve implantation (TMVI) device was featured in a live case that was broadcast at the 2018 Transcatheter...

Neovasc provides Tiara clinical update

Neovasc has provided an update on the study progress and clinical performance of the Tiara valve, a self-expanding mitral bioprosthesis for transcatheter implantation in...

German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application

The District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corporation (formerly CardiAQ Valve Technologies) in its case against Neovasc.  In...

Boston Scientific closes acquisition of certain Neovasc assets

Boston Scientific Corporation has closed its acquisition of certain manufacturing assets and capabilities of the Neovasc advanced biological tissue business. With the completion of...

Neovasc receives approval to launch European study of Tiara transcatheter mitral...

Neovasc has received both regulatory and ethics committee approval to initiate the Tiara transcatheter mitral valve replacement study (TIARA II) in Italy. The study...

TCT 2016: Tiara TMVI device highlighted in presentations

Neovasc has announced today its notable presentations at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA). On 31 October,...

FDA gives Neovasc go-ahead to add 40mm valve size to its...

The FDA has given Neovasc approval for participating physicians to treat patients with the company’s 40mm Tiara valve in its TIARA-I early feasibility trial. The...